Australian melanoma pioneer Richard Scolyer dies after experimental brain tumour treatment
By
Tiffanie Turnbull
Slow-proofed and worth the wait. Worth its weight in flour.
Summary
Dr. Richard Scolyer, a pioneering Australian melanoma researcher, has died at age 59 from glioblastoma, three years after his diagnosis. He underwent a risky world-first experimental treatment for his aggressive brain tumor, developed from his own groundbreaking melanoma research with colleague Professor Georgina Long. Their work transformed advanced melanoma from a death sentence into a treatable condition, saving countless lives. Scolyer's experimental brain cancer treatment, while ultimately unable to save him, has sparked hope and provided valuable data for future breakthroughs in glioblastoma research.
Key quotes
· 3 pulledPioneering Australian doctor Richard Scolyer has died, three years after being diagnosed with an aggressive brain tumour.
Scolyer, 59, made global headlines for his decision to undergo a risky world-first experimental treatment for his glioblastoma at the hands of his friend Professor Georgina Long - based on the pair's own scientific breakthroughs in skin cancer.
Their work on advanced melanoma - once a death sentence - has saved countless lives, and their encouraging finding
You might also wanna read
Professor Richard Scolyer, pioneering melanoma doctor and Australian of the Year, dies from brain cancer
Professor Richard Scolyer, a globally renowned Australian melanoma specialist and 2024 Australian of the Year, has died after a battle with
bbc.co.uk·1d ago:max_bytes(150000):strip_icc():focal(749x0:751x2)/Ashley-McCrary-050626-1-32b37e07096940718dc051ca958bee11.jpg)
Rare Eye Cancer Patient Outlasts 18-Month Prognosis, Now Helps Others Afford Travel for Treatment
Ashley McCrary, a mother of four, was diagnosed with a rare eye cancer that spread to her lung and breast, given an 18-month prognosis. Rath
People.com·1mo ago
Personalized glioblastoma vaccine shows safety and survival promise in phase 1 trial
A phase 1 clinical trial at Siteman Cancer Center found that a personalized vaccine for glioblastoma, an aggressive brain cancer, is safe an
flip.it·8d ago
Personalized mRNA vaccine combined with Keytruda shows 49% reduction in melanoma recurrence risk
An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined
npr.org·5d agoPersonalized mRNA vaccine combined with Keytruda shows 49% reduction in melanoma recurrence risk
An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined
npr.org·5d ago:max_bytes(150000):strip_icc()/Juliet-Fielder-dies-lung-cancer-052626-f4cb12d2568949d9ad38a1fc575d49a1.jpg)
Non-Smoker Dies of Lung Cancer at Age 42, 4 Years After Diagnosis
UCL researchers warn LED lighting may harm human mitochondria, call it a public health crisis
New research from University College London (UCL) by Dr. Glen Jeffery and Dr. Edward Barrett reveals that standard LED lights, which emit hi